The first 'International Podocyte Conference' was held in Freiburg in 1999 and focused on the understanding of different isolated aspects of podocyte biology. Since then the field has continuously moved forward unraveling the complex integration of podocyte and glomerular biology into the pathophysiological understanding of primary and secondary glomerular diseases. This review shall briefly summarize the current status of podocyte and glomerular biology as it has been presented and discussed during the 2014 International Podocyte Conference (Figure 1 ).
GLOMERULAR CROSS TALK
During the last couple of years, it has become more and more evident that the cells within the glomerular tuft influence each other via paracrine mechanisms ( Figure 2 ). 1 This function was first established for VEGF-A, which under physiological conditions is regulated in a tightly titrated manner, as both a gradual reduction or an increase in VEGF-A leads to severe glomerular pathologies. [2] [3] [4] [5] Although podocyte-derived VEGF-A mainly signals to VEGFR-2 on glomerular endothelial cells, there is also an interesting autocrine loop for podocytes, which relies on VEGFR-1 but not VEGFR-2 signaling. 6 Surprisingly, the soluble variant of VEGFR-1 (sFLT1) seems decisive in mediating this essential loop to maintain podocyte cell morphology and hence glomerular barrier function. It does so by binding to the glycosphingolipid GM3 in lipid rafts on the outside of podocytes, which in turn promotes adhesion and actin reorganization. 6 New evidence points to the specificity of the respective splice isoform of VEGF being involved in this function. VEGF165b has been shown in vitro and in vivo to be neuroprotective and appears to fulfill a similar role in the kidney. 7 Thus, transgenic mice expressing this isoform are at least partially protected from diabetic albuminuria.
Besides VEGF, new paracrine signaling molecules are entering the stage. One of the most recent examples is endothelin-1, which is produced in podocytes upon stimulation of the TGF-cascade, as it occurs in FSGS (focal segmental glomerular sclerosis) or adriamycin-induced glomerulosclerosis. 8 Endothelin-1 via the endothelin receptor Type A leads to endothelial dysfunction, which in turn augments podocyte stress, finally leading to podocyte depletion. 8 Interestingly, there also seem to be signals that originate in the endothelial cells and relay on to the podocyte. One such example is the thrombomodulin-dependent formation of activated protein C by glomerular endothelial cells. Activated protein C in turn modulates the mitochondrial apoptosis pathway via protease-activated receptor1 (PAR-1) and the endothelial protein C receptor (EPCR), thereby preventing podocyte apoptosis. 9 During glomerular stress as occurs with high glucose in diabetic patients, this pathway is disturbed leading to increased glomerular damage and finally contributing to diabetic nephropathy. 9 Besides the factors mentioned above, there seem to be several others, both of local and systemic origin, which either seem to protect podocytes from injury or modulate injury responses by altering intracellular pathways. [10] [11] [12] Besides the tight interaction between endothelial cells and podocytes across the glomerular basement membrane (GBM), there seems to be potentially equally important cross talk between podocytes and parietal epithelial cells. 13 Presently, research tries to enlighten the signaling pathways involved in this delicate balance between visceral and parietal epithelial cells across Bowman's space. In addition to the initially described HB-EGF pathway in RPGN (rapid progressive glomerulonephritis), more overarching regulators such as miRNAs are recognized and probed as effectors and potential therapeutic targets. 13 Podocytes seem to be versatile players in these intercellular exchanges communicating with all neighboring cells.
In addition, podocytes take center stage for generating and modifying the GBM, for example, in the Alport Syndrome with mutations in the COL 4 chains of the GBM. Despite the improvement in the progression of the disease with RAS blockade, Alport syndrome remains the most frequent monogenetic cause of glomerular disease leading to endstage renal disease. 14 A preclinical proof of concept trial showed that establishing normal Col4a3 expression in adulthood can considerably prolong survival in Col4a3 À / À Alport mice. 15 In addition, there is new evidence from genetic manipulation in Alport mice that filtered albumin is indeed injurious for podocytes and/or tubular epithelial cells, thereby contributing to the progression of disease (unpublished, reported by Dr Jeff Miner). These data further support the use of antiproteinuric therapies such as RAS blockade in patients with Alport syndrome and perhaps in other genetic, proteinuric glomerular diseases as well.
INSIGHTS FROM GENETICS
Identification of genetic mutations in hereditary and sporadic FSGS, and the nephrotic syndrome has greatly increased since the advent of next-generation sequencing techniques. 16, 17 Yet, currently only approximately 30% of suspected genetic FSGS cases can be explained by known affected genes, whereas in 70% the etiology remains m e e t i n g r e p o r t obscure. 16, 18 Similar data have been recently obtained by a study of 48 SRNS (steroid resistant nephrotic syndrome) samples from a worldwide cohort. 19 Furthermore, the chance of finding a monogenetic cause of SRNS is diminishing with later disease onset and smaller size of the established pedigree. Concomitantly, the percentage of recessive alleles is declining with age, whereas autosomal dominant genes are increasing.
Novel mutations detected to contribute to FSGS cluster around genes involved in actin binding, actin regulation, and mitochondrial function in podocytes. [19] [20] [21] [22] Surprisingly, the homozygous missense mutation p.P209L in the ciliary transport protein IFT139 (TTC21B) could be linked to a clinical phenotype comprising both FSGS and nephronophthisis. 23 This is even more challenging as affected family members developed end-stage renal disease only by 22 years of age, whereas cilia are thought to disappear from podocytes after glomerular maturation, which in humans is accomplished at birth. Therefore, it has been proposed that IFT139 might have a role for stabilization of the actin cytoskeleton and protein trafficking besides its ciliary functions. 23 Similarly, a 129 kb deletion on chromosome three unraveled the important role of the IQCJ gene cluster for podocyte maintenance (unpublished, reported by Dr Rachel Lennon). This gene either leads to an IQ domain containing protein J or leads to a fusion protein with the contiguous gene SCHIP1. The aforementioned deletion upstream of IQCJ leads to global glomerular sclerosis. Most unexpectedly, IQCJ seems to be a neo-antigen after transplantation potentially leading to membranous nephropathy post transplant. On a cell biological level, IQCJ knockdown in zebrafish leads to severe edema and significant foot process effacement. Bioinformatic modeling hints to a potential role of this protein for vesicle transport, vesicle fusion, secretory vesicles, and proteasome function. This is confirmed by colocalization studies confirming proximity with endosomal and autophagic markers (unpublished, reported by Dr Rachel Lennon).
On the other hand, despite clear genetic evidence for gene involvement in FSGS, it often remains a difficult task to understand the patho-mechanisms leading to the clinical phenotype as is the case for, e.g., INF2. 24 Interestingly, the pathogenic role of the frequent p.R229Q polymorphism in the NPHS2 gene for late-onset SRNS has now been solved. [25] [26] [27] The second mutated NPHS2 allele only leads to altered dimerization and mislocalization of p.R229Q PODOCIN if its mutation is in exon 7 or 8. This can hence lead to a challenging pedigree with variable disease frequencies depending on the co-occurring NPHS2 mutations within a certain family. 27 In addition, in the African and Afro-American population, the high frequency APOL1 risk alleles can lead to pseudo-dominant FSGS. Despite major discoveries over the last years, the exact role of the APOL1 protein in kidney disease progression still remains largely elusive. 24, [28] [29] [30] This is due to several technical difficulties: (i) established disease models in animals like mice lack the ApOL1 gene; (ii) APOL1 is toxic to cultured cells; (iii) although genetics suggest a recessive mode of inheritance, null mutants do not develop disease; (iv) in human tissues, APOL1 is widely expressed and the role of systemic versus renal expression remains to be determined; and finally (v) environmental factors seem to have a major role in disease development. 31 Hence, major efforts are underway to establish an inducible cell culture system and transgenic mouse models expressing the three human risk variants G0, G1, and G2. Further epidemiological data meanwhile underline the importance of the APOL1 risk variant G2 for more rapid progression of chronic kidney disease in African Americans. [32] [33] [34] 
TRANSLATIONAL GLOMERULAR MEDICINE
In several glomerular disease entities, groundbreaking basic science research is on the verge of being translated into clinical type I/II therapeutic trials, aiming at a successful bench to bedside transition ( Figure 3 ). Such novel and pioneering therapeutic approaches are especially important, as currently there are no established causal therapies available for most of the glomerular diseases to be discussed below.
Preeclampsia is defined as the new onset of hypertension and either proteinuria or end-organ dysfunction after Recent discoveries propose several disease-modifying pathways, which might help to treat proteinuric kidney diseases. B7-1 shows an increased expression in a subset of proteinuric kidney diseases. Its deleterious action on the actin cytoskeleton might be blocked by abatacept. Besides its action on antibody-producing B-cells, the CD-20 antibody rituximab might directly improve podocyte function by acting on SMPDL-3b. Modification of diseaseinduced expression of Angptl4 might reduce proteinuria not only in MCD but also in other proteinuric kidney diseases. The actin cytoskeleton, which is affected in all kinds of glomerular diseases, might be targeted by modification of dynamin, which can be induced with Bis-T-23. Inhibition of TRPC5 channels, which mediated increased Ca 2 þ fluxes during disease, has reduced proteinuria in experimental models. 3 Integrins seem to be activated via suPAR and their inhibition with cycloRGDfV might abrogate their activation not only in FSGS but potentially also in other proteinuric glomerular diseases. FSGS, focal segmental glomerular sclerosis; MCD, minimal change disease.
20 weeks of gestation in a previously normotensive gravida. 35 Pathophysiologically placental dysfunction contributes to grossly increased sFLT-1 levels, which in turn cause widespread maternal systemic endothelial damage, leading to hypertension, proteinuria, liver dysfunction, and in worst cases cerebral edema and seizures. For the fetus, growth retardation due to placenta dysfunction and increased cardiovascular risk later in life are the main sequelae. 36 So far, no pharmacological intervention successfully prevents or treats preeclampsia, so that the only treatment is delivery of the child. Depending on the gestational age, this obviously entails tremendous risks for the prematurely delivered child. In order to reduce the levels of sFLT1, two different apheresis approaches have been used (negatively charged dextran sulfate cellulose or heparin-mediated extracorporeal lowdensity lipoprotein precipitation). Initial results from pilot trials using these two methods indicate successful and safe prolongation of time to delivery. 37, 38 Because of procedural issues, the extent of sFLT1 reduction is different between the two techniques, raising anew the question of the exact contribution of sFLT1 to this disease process.
FSGS probably represents more of a histopathological diagnosis based on the pattern of injury rather than a single disease entity. Expert opinion estimates genetic causes to be responsible in 20%, a circulating factor in 30%, and other causes in the remaining 50% of cases. Although genes associated with FSGS have been discussed earlier, there is still scientific dispute regarding the pathophysiological relevance of the recently identified soluble FSGS factor suPAR in human FSGS patients. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Further studies will be needed to clarify the role of suPAR and other potential soluble factors involved in the pathogenesis of FSGS.
Gain of function mutations in TRPC6 are a rare hereditary cause of FSGS. 49, 50 Pathophysiologically increased Ca 2 þ permeability probably leads to increased activation and stiffness of the actin cytoskeleton, which over time leads to increased stress and finally to loss of podocytes. Interestingly, podocytes not only contain TRPC6 but also the highly related TRPC5 channel, and these two channels seem to exert an antagonistic regulation of actin dynamics and cell motility. 51 Although TRPC6 seems to have pathological relevance in rare genetic cases, TRPC5 seems to be activated in many acquired proteinuric diseases. 52 Indeed, the inhibition of TRPC5 or genetic knockout in animal models of proteinuria or foot process effacement improved disease severity.
Serendipity led to the discovery of the potential role of miRNA-193a in the pathogenesis of FSGS. 53 Inducible overexpression of miRNA 193 led to FSGS over the course of 6 weeks. miRNA interferes with the transcription factors WT-1 and ATOH-8. At least the former is not only relevant for glomerular development but similarly critical for podocyte maintenance. Hence, WT-1-dependent genes--i.e., Podxl, Synpo, Nphs1, Nphs2, Inf2, Fat1, Cd2AP, or Actn4--were all extensively downregulated by miRNA 193. Interestingly, miRNA 193 expression is high within the nephrogenic zone during development but diminishes with further differentiation of podocytes. Within the adult glomerulus, miRNA 193 is highly expressed in parietal epithelial cells and could contribute to the pathological responses seen in FSGS or crescent formation. 54 Already 10 years ago, it could be shown that the protein B7-1, which is part of the T-cell co-stimulatory pathway, gets upregulated in proteinuric animal models and humans with the nephrotic syndrome. 55 Very recently, inhibition of B7-1 with abatacept in five patients with primary or recurrent FSGS was reported to lead to partial or complete disease remission. 56 Intriguingly, these patients had failed standard therapy before. Analyzing different nephrotic disease entities, the authors found B7-1 expression in a subset (13/22) of samples of FSGS, minimal change disease, lupus nephritis, and IgA nephritis. This observation generated the hypothesis that there might be a subset of nephrotic diseases where B7-1 has a pathogenetic role and in which inhibition of B7-1 might ameliorate the course of the disease. Clearly, a prospective and randomized trial will be needed to test the role of abatacept as a new anti-proteinuric drug.
Similar to FSGS, the pathogenesis in minimal change disease is incompletely understood. Reports from one group support a role of Angptl4 in the pathogenesis of this disease entity. [57] [58] [59] They showed that plasma ANGPTL4 levels in patients with the nephrotic syndrome are highest in minimal change disease and that transgenic overexpression of Angptl4 in podocytes of rats leads to the typical features of minimal change disease. 57, 58 Mechanistically, ANGPTL4 inhibits av5 INTEGRIN, thereby maintaining proteinuria. By favoring its own production in skeletal muscle, heart, and adipose tissue, ANGPTL4 is postulated to maintain a vicious circle. Experimental administration of either mutated or sialylated ANGTPL4 could reduce proteinuria in animal models. Further developments and confirmations of these exciting data are eagerly awaited.
CYTOSKELETON
The actin cytoskeleton has a pivotal role in maintaining the 3-D architecture of the interdigitating foot processes. The actin cytoskeleton itself can be divided into a cortical or subcortical actin network and into a central actin bundle. 60 These two subsystems seem to have different cellular functions. The subcortical actin is, e.g., linked to integrins and hence is involved in the formation of focal adhesions and in interactions with in the case of podocytes the glomerular basement membrane. These adhesions are tightly regulated and many important kinases and modulators--e.g., TALIN, VINCULIN, PAXILIN, FAK, ILK, and others-are located at these interaction sites. 61 Indeed, these outside-in connectors are probably regulated very finely in a context-dependent manner. As could be shown recently, the extracellular matrix of the GBM is composed of many more proteins than previously thought, and its composition is changed depending on the interaction between podocytes and endothelial cells. 62, 63 It is tempting to speculate that these changes in the GBM will be reflected by changes of the anchoring system of the cortical actin cytoskeleton, thereby influencing the overall stability and adherence of podocytes onto the GBM. In recent years, it could be shown that a plethora of actin regulators--i.e., NCK, DYNAMIN, SYNAPTOJANIN, ENDOPHILIN, COFILIN, or N-WASP--are necessary for the organized flow of the actin 'life cycle' consisting of actin polymerization, actin branching, and actin severing, and loss of these proteins leads to severe glomerular injury. [64] [65] [66] [67] [68] [69] How exactly this regulatory network operates is still incompletely understood. Yet, it seems probable that therapies targeted to specific players of this network might have the potential of positively influencing proteinuric diseases, potentially even irrespective of their molecular origin. 70 
CELL METABOLISM
During the last years, the response of podocytes to metabolic stressors has become a central theme in translational research of glomerular biology. This interest is fueled by the worldwide epidemic of diabetic nephropathy, which is the leading cause for end-stage renal disease in developed and some developing countries as well. 71 Hence, insulin, its receptors, downstream signaling pathways and mediators such as glucose transporters, AKT, and mTOR or cellular organelles--e.g., endoplasmic reticulum and mitochondria--are the focus of research on diabetic nephropathy. Although the detrimental effects of elevated insulin and glucose levels on podocytes are widely recognized, abrogating the insulin signal by podocytespecific knockout surprisingly also leads to glomerulosclerosis and kidney failure. 72 This occurred despite the fact that there seems to be a receptor redundancy between the IGF and the insulin receptor. 73 Hence, it is necessary to maintain a titrated insulin/IGF receptor-mediated signal output. This signaling balance is reminiscent of the mTOR pathway in podocytes, which is also a major downstream effector of the insulin/IGF network. 74, 75 Paradoxically, both podocyte-specific knockout of mTORC1 and mTORC1 hyperactivation by knockout of TSC1 lead to proteinuria and glomerulosclerosis; yet, haploinsufficiency of mTORC1 could ameliorate diabetic phenotypes in two murine models of diabetic nephropathy. 74, 75 At present, it remains unclear how the delicate balance of mTOR signaling is achieved physiologically, and which are the most important downstream signaling mediators. Furthermore, the exact interplay of mTOR as an inhibitor of autophagy remains to be resolved, as autophagy is essential for podocyte homeostasis. 76, 77 The complexity of mTOR's function is further illustrated by its activation contributing to diabetic nephropathy on the one hand, yet on the other hand, it is also essential for compensatory nephron hypertrophy after nephron reduction. Surprisingly, in this function, there is also an important contribution of mTORC2 besides mTORC1, which mediates the growthrelated effects. 78 Thus, mTORC2 via its downstream mediator Akt2 is necessary to mediate podocyte adaptation to nephron reduction in mice and humans by preventing apoptosis and foot process effacement. mTORC2 achieves stabilization of podocyte function by activating downstream signaling effectors such as Mdm2, Gsk3, and Rac1 and thereby retards the development of proteinuria and glomerulosclerosis. 78 
REGENERATION
During the last decade, research into the regenerative potential of podocytes has gained increasing interest, as causal therapies for glomerular diseases are still lacking. However, data between different models and approaches are still conflicting, and there is no accepted consensus on the amount of regeneration taking place during injury and the cells that could mediate this replacement if it exists at all. Several potential progenitor niches have been described in both rodents and humans. [79] [80] [81] [82] [83] [84] Especially, parietal epithelial cells have attracted attention as they are descendants of the same epithelial lineage as podocytes and reside in close proximity to the glomerular tuft, thereby potentially enabling a transdifferentiation. 79, 83 Meanwhile, it could be shown that certain factors either boost or inhibit differentiation from parietal epithelial cells into podocytes. At least under in vitro culture conditions, Notch activation and retinoic acid promote this cell type switch, whereas albumin seems to sequester retinoic acid, thereby reducing podocyte regeneration. [85] [86] [87] Yet, two recent publications indicate that in vivo there is no significant podocyte regeneration during aging or compensatory hypertrophy. 88, 89 This not only applies to regeneration from the parietal epithelial cell niche but also to any potential regeneration from the bone marrow niche. 89 Only acute podocyte ablation using an inducible diphtheria toxin receptor model led to a modest regenerative response. 89 Future studies will be needed to further define the circumstances and factors being involved in potential glomerular regeneration. In this respect, the aforementioned study on the sequestration of retinoic acid by albumin might give an explanation why we can hardly detect podocyte regeneration in an in vivo setting. 85 With regard to parietal epithelial cells, it might be that they have a more important role in pathological processes related to glomerulosclerosis rather than in podocyte regeneration. 90, 91 Indeed, it could be shown that parietal epithelial cells participate in crescent formation at least in rapid progressive glomerulosclerosis and FSGS. 91, 92 
SLIT DIAPHRAGM
The delicate podocyte slit diaphragm, which among others is formed by NEPHRIN, NEPH1, and PODOCIN, is well conserved in the animal kingdom including model organisms--i.e., C. elegans or D. melanogaster. 93, 94 Although it is unclear whether mammalians have a cis-or trans-interaction of NEPHRIN and NEPH1, it is well established that the C. elegans homologues SYG-1 (NEPH1) and SYG2 (NEPHRIN) interact in trans-configuration to form synapses between guidepost cells and the hermaphrodite-specific neuron axon. Recent work has explored the structural characteristics of these two proteins. 95 The similar structures of the Ig folds are intriguingly well conserved from fly to man. Heterologous SYG1 and SYG2 proteins interact through a peculiar 901-1101 quasi-orthogonal binding and form rigid molecules. This bended structure seems of great importance as evidenced by substitution experiments, where only molecular combinations preserving this angle can at least partly rescue synapse formation in hermaphrodite-specific neurons. 95 Similar to the distance of the mammalian slit diaphragm, the distance between guidepost cell and hermaphrodite-specific neuron is approximately 45 nm. Further studies will prove whether this model can be applied to the molecular organization of the slit diaphragm.
Besides giving structural insights into the morphology of the slit diaphragm, model organisms--i.e., D. melanogaster--can be used to screen for genes involved in podocyte function. 96 Indeed, when ADCK4 was discovered as a gene responsible for SRNS, this phenotype could be recapitulated in Drosophila nephrocytes as equivalents of mammalian podocytes. 96 Yet, it has to be taken into account that the nephrocyte does not only contain intracellular slits but also has a highly developed endocytotic machinery, which rather resembles proximal tubular cells. Hence, it is not surprising that two genes previously linked to endocytosis (CG32702 homologue of CUBN (CUBILIN) and CG11592 homologue of AMN (AMNIONLESS)) also caused severe defects in Drosophila nephrocytes. 97 Besides NEPHRIN's structural function, several lines of evidence suggest that it also exerts an important signaling function. 66, 98, 99 Recent data propose that downstream of NEPHRIN the cytoskeletal adaptor proteins CRK1/2 and CRKL are essential to mediate foot process effacement. 100, 101 Knockout of CRK1/2 or CRKL prevents foot process effacement in the well-established protamine sulfate model, whereas knockout of both molecules leads to altered podocyte foot process architecture and albuminuria, suggesting an additional developmental function for these molecules. 101 
TECHNICAL ADVANCES
Four major technical advances have raised hope for a better understanding of glomerular biology and more rapid investigation of pathomechanisms of glomerular diseases: (i) Imaging techniques, (ii) refinement of genetic techniques and better genotype-phenotype correlation, (iii) improvement in model organisms, and (iv) exploitation of proteomic techniques.
Traditionally, investigations on the filtration barrier have been hampered by the complex 3-D structure of the kidney and difficulties imaging the fine ultrastructure of podocyte foot processes. During the last couple of years, several exciting new techniques could be adopted for the use in glomerular research. [102] [103] [104] The Nobel Prize winning invention of nanoscopy techniques--i.e., STED (STimulated Emission Depletion Microscopy) and STORM (STochastic Optical Reconstruction Microscopy)--has enabled the visualization of podocyte foot processes and diseaseinduced dynamics by light microscopy. [104] [105] [106] In addition, correlation of these techniques with electron microscopy pictures of the same specimen is now feasible and gives further valuable insights into protein distribution within subcellular structures. Probably, equally exciting are the advances in the field of intra-vital microscopy. Using genetically modified animals and two photon laser scanning microscope set-ups, it is now possible to track physiological and pathological changes within one defined glomerulus even over a period of several days. 102 In addition, cell-type-specific expression of intracellular Ca 2 þ indicators allows monitoring of intracellular signaling events in living animals. 103 Next-generation sequencing, and especially exon sequencing, has tremendously accelerated the pace of discovery for rare genetic kidney disease variants. 107 Yet, with ever-rarer variants, statistical analysis and power, as well as careful choice of the appropriate selection strategy for both index patients and chosen controls require more and more sophisticated analysis. 108 One possibility to further enhance the chance of finding relevant variants is to closer correlate genetic information with more clinical specimen and patient histories (genotype-phenotype correlation). This is the ambitious aim of a large-scale initiative called 'NEPhrotic Syndrome STUdy NEtwork (NEPTUNE)'. 109 Combining nearly 500 phenotype parameters, a state-of-the-art digital pathology evaluation and management system, with wholegenome sequencing, glomerular and tubular transcriptomics, and targeted proteomics holds the power to establish a new nephrotic syndrome taxonomy, which eventually could also lead to novel, more target-oriented treatment strategies. 109, 110 Besides the classical mammalian model organisms Mus musculus and Rattus norvegicus, there have been recent advances in making use of the easy genetic manipulation in the fruit fly (D. melanogaster) and the zebrafish (D. rerio) to more widely use these models in the search for fundamental answers in podocyte research. As outlined above, D. melanogaster holds the potential of a cost-effective genome-wide screening tool to identify genes relevant for nephrocyte function. 96 In contrast to the fruit fly, zebrafish have a glomerulus, which closely resembles their mammalian counterparts. 111, 112 Especially, for in vivo imaging, the zebrafish has considerable advantages because of its glomerular structure containing endothelial cells, GBM, mesangial cells, podocytes, and a developed vascular system over the more basic detoxification system of, e.g., the fruit fly. 113 With the advent of ever-improving mass spectrometry equipment, proteomics becomes more and more an integral part of unbiased cell-specific analysis accompanying genomics and transcriptomics. 63, 114, 115 Mass spectrometry does not only help identify proteins but represents also a powerful tool to perform functional signaling analysis, thereby bridging the gap to genetics. In a study using native mouse glomeruli as starting material, 120 out of 4079 class I phosphorylation sites could be identified on podocyte-specific proteins. Interestingly, phosphorylation on PODOCIN T 234 could be shown to be important for PODOCIN Dimer stabilization. Known mutations at this side lead to dimer destabilization after phosphorylation. 114 Further techniques, such as the transfer of SILAC (Stable Isotope Labeling by Amino acids in Cell culture) to in vivo models, hold the potential of quantifying protein turnover under physiological and pathological conditions. 116 
CONCLUSION
Over 300 participants witnessed and contributed to the breathtaking acceleration of discoveries in the field of podocyte biology and glomerular disease at the 10th International Podocyte Conference in Freiburg. New technologies such as super-resolution imaging, in vivo imaging, 'omics' methods, and systems biology combined with large patient registry-based efforts in genetic and clinical investigation have been the driving force for most of the discoveries and allowed novel treatment options to be considered and discussed throughout the entire meeting. Therefore, most participants left the meeting with an upbeat mood and the feeling that although there is still a tough road ahead of us, we may be on the verge of implementing patient-specific strategies based on the individual molecular pathogenesis to better diagnose, predict, prevent, and treat various glomerular diseases. Finally, the congenial and open spirit of the meeting was proof that excellent science can also be good fun.
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